Informazione:
Errore:
ID
32706
Descrizione
Study ID: 107038 Clinical Study ID: LPL107038 Study Title: Study to Estimate the Dose Proportionality of the Enteric-Coated Freebase Formulation of SB-480848 Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: Tyrisa ,US Study Indication: Atherosclerosis
Keywords
versioni (1)
- 13/11/18 13/11/18 -
Titolare del copyright
GSK group of companies
Caricato su
13 novembre 2018
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY-NC 3.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
Estimation of Dose Proportionality of Darapladib - 107038
Logs and Repeats: General Adverse Event and Concomitant Medication Questions
Similar models
Logs and Repeats: General Adverse Event and Concomitant Medication Questions
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Date below is the start of the study for this subject
Item
Date below is the start of the study for this subject
date
Item Group
Adverse Event/Concomitant Medications/Repeat Assessment (Check Questions)
Were any concomitant medications taken by the subject during the study?
Item
Were any concomitant medications taken by the subject during the study?
boolean
Did the subject experience any adverse events during the study?
Item
Did the subject experience any adverse events during the study?
boolean
Were any repeat ECGs performed?
Item
Were any repeat ECGs performed?
boolean
Were any repeat/unscheduled PK samples taken?
Item
Were any repeat/unscheduled PK samples taken?
boolean
Were any repeat/unscheduled PD samples taken?
Item
Were any repeat/unscheduled PD samples taken?
boolean